Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Moderate Buy — five analysts average a "Moderate Buy" rating (1 sell, 3 buy, 1 strong buy) with a 1‑year target of about $18.67.
• Institutional buying — several funds have increased or initiated positions recently, notably Bank of America boosting its stake by 225.8% and Renaissance Technologies holding 116,200 shares after adding 37,053.
• Stock and company snapshot — ARTV traded at $5.09 (1‑year range $1.47–$7.75) with a market cap of ~$125.7M; Artiva is a clinical‑stage developer of allogeneic "off‑the‑shelf" NK CAR cell therapies and reported Q EPS of −$0.84 (beat −$0.87) with FY EPS expected around −4.95.

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $18.6667.

ARTV has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, January 27th.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at about $41,000. OMERS ADMINISTRATION Corp bought a new position in shares of Artiva Biotherapeutics in the fourth quarter valued at about $91,000. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth about $53,000. Finally, Renaissance Technologies LLC grew its holdings in Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company's stock worth $498,000 after acquiring an additional 37,053 shares during the last quarter.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV traded down $0.07 during trading on Friday, reaching $5.09. 29,306 shares of the company traded hands, compared to its average volume of 180,525. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $7.75. The company has a market cap of $125.71 million, a price-to-earnings ratio of -1.51 and a beta of 2.16. The stock's 50 day moving average price is $4.95 and its two-hundred day moving average price is $4.12.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.03. Equities research analysts expect that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.